Amycretin
GLP-1 receptor agonist and amylin receptor agonist
From Wikipedia, the free encyclopedia
Amycretin (development code NN 9487) is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.[1][2][3][4][5] A subcutaneous injection formulation is being developed in parallel.[6]
| Clinical data | |
|---|---|
| Other names | NN 9487; NN9487; NNC0487-0111 |
| Identifiers | |
| CAS Number | |
The drug's dual mechanism of action, which affects appetite regulation (through the GLP-1 receptor) and metabolism (through the amylin receptor), distinguishes it from existing weight loss medications. It contains two covalently linked peptides that are analogs of GLP-1 and amylin respectively. The oral formulation contains salcaprozate sodium (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate; SNAC) as a permeation enhancer.[6]
Clinical trials
On 7 March 2024, the company announced the results from the Phase I trial of the pill form of amycretin.[7][8][9]
In January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Treatment duration was up to 36 weeks.[10][11]
Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecast the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.[7]